Loading…
RGEN · NASDAQ · Biotechnology
Biotechnology company based in Waltham, Massachusetts.
In the last 90 days, no insider of Repligen reported an open-market purchase and 8 open-market sales worth about $6.03M. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$189.50
Last 12 months
Not enough history
Market value
$10.7B
Revenue
$204M
+11.9% vs the same quarter a year earlier
Free cash flow, last 12 months
$112M
This quarter $27.4M, a year earlier $21.5M
Net cash
$55.7M
Debt $551M, cash $607M, at Jun 30, 2026
Net income, last 12 months
$41.5M
Operating profit covers interest 2.9x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Jul 28, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
8 sales
$6.03M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$738M
+16.4% vs the year before
Net income, fiscal 2025
$48.9M
As reported in the annual filing
Shares outstanding
56.4M
As of Jul 24, 2026
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last 12 months, adjusted daily closes
Adjusted close went from $150.10 on Oct 6, 2025 to $189.50 on Oct 5, 2026 (+26.2%). Disclosed activity in the last 12 months: 0 insider purchases, 25 insider sales (16 under pre-arranged plans), 0 Congress purchases, 0 Congress sales.
Top officer leaving
“With a successful CEO transition complete, I believe now is the right time for my retirement.”
1 insider sold ~$1.48M in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.